MDGL · Nasdaq · ·
Next earnings: November 3, 2026
$508.58-1.8%Sep 29 close
Madrigal Pharmaceuticals, Inc. is scheduled to report next on November 3, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $364.3M | $212.8M | +71.17% |
| Profit | -$57.9M | -$42.3M | -37.03% |
| Profit per share | -$1.99 | -$1.50 | -32.67% |
| Free Cash Flow | $19.1M | -$47.1M | +140.54% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Releases land after the close or before the open, so the move is the session that follows.
Metabolic dysfunction-associated steatohepatitis (MASH) is a serious liver disease that can progress to cirrhosis, liver failure, liver cancer, the need for liver transplantation, and premature mortality. MASH is the leading cause of liver transplantation in women and the second leading cause of all liver transplantation in the U.S. It is the fastest-growing indication for liver transplantation in Europe. Once patients progress to MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), the risk of adverse liver outcomes increases dramatically: these patients have a 10 to 17 times higher risk of liver-related mortality as compared to patients without fibrosis. Patients with MASH who progress to cirrhosis face a 42 times higher risk of liver-related mortality, underscoring the need to treat MASH before complications of cirrhosis develop. MASH is also an independent driver of cardiovascular disease, the leading cause of mortality for patients. As disease awareness improves and disease prevalence increases, the number of diagnosed patients with F2 to F4c MASH is growing.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Madrigal Pharmaceuticals, Inc.’s Item 2.02 8-K filed July 30, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Madrigal Pharmaceuticals, Inc. has no earnings call transcript available.